Henry Ruiz-Garcia1, Daniel M Trifiletti1, Nasser Mohammed2, Yi-Chieh Hung2, Zhiyuan Xu2, Tomas Chytka3, Roman Liscak3, Manjul Tripathi4, David Arsanious5, Christopher P Cifarelli5, Marco Perez Caceres6, David Mathieu6, Herwin Speckter7, Gregory P Lekovic8, Gautam U Mehta8, Jason P Sheehan9. 1. Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA; Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA. 2. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA. 3. Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic. 4. Post Graduate Institute of Medical Education and Research, Chandigarh, India. 5. Department of Neurological Surgery, West Virginia University, Morgantown, Virginia, USA. 6. Department of Neurological Surgery, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 7. Dominican Gamma Knife Center and CEDIMAT Hospital, Santo Domingo, Dominican Republic. 8. House Ear Institute, Los Angeles, California, USA. 9. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA. Electronic address: jsheehan@virginia.edu.
Abstract
BACKGROUND: Convexity meningiomas are common tumors requiring treatment in patients with neurofibromatosis type 2 (NF2). Although different therapeutic options are described for sporadic convexity meningioma, much less is known about these lesions in patients with NF2 despite their distinct biology and need for multiple treatments. We analyzed the value of Gamma Knife radiosurgery (GKRS) as definitive treatment for convexity meningiomas in patients with NF2. METHODS: This international multicenter retrospective study was approved by the International Radiosurgery Research Foundation. Patients with NF2 with at least 1 convexity meningioma and 6-month follow-up after primary GKRS were included. RESULTS: Inclusion criteria were met by 18 patients with NF2. A total of 120 convexity meningiomas (median treatment volume, 0.66 cm3 [range, 0.10-21.20 cm3]) were analyzed. Median follow-up after initial GKRS was 15.6 years (range, 0.6-25.5 years). Median age at GKRS was 32.5 years (range, 16-53 years). Median number of meningiomas per patient was 13 (range, 1-27), and median number of convexity lesions receiving GKRS per patient was 3.5 (range, 1-27). One case of tumor progression was reported 24 years after GKRS, leading to actuarial progression-free survival rates of 100% at 2, 5, and 10 years. No malignant transformation or death due to meningioma or radiosurgery was recorded. CONCLUSIONS: GKRS is safe and effective as definitive treatment of small to medium-sized convexity meningiomas in patients with NF2. Despite concerns about the particular mutational burden of these tumors, no malignant transformation manifested after treatment. GKRS represents a minimally invasive option that offers long-term tumor control to this specific group of patients.
BACKGROUND: Convexity meningiomas are common tumors requiring treatment in patients with neurofibromatosis type 2 (NF2). Although different therapeutic options are described for sporadic convexity meningioma, much less is known about these lesions in patients with NF2 despite their distinct biology and need for multiple treatments. We analyzed the value of Gamma Knife radiosurgery (GKRS) as definitive treatment for convexity meningiomas in patients with NF2. METHODS: This international multicenter retrospective study was approved by the International Radiosurgery Research Foundation. Patients with NF2 with at least 1 convexity meningioma and 6-month follow-up after primary GKRS were included. RESULTS: Inclusion criteria were met by 18 patients with NF2. A total of 120 convexity meningiomas (median treatment volume, 0.66 cm3 [range, 0.10-21.20 cm3]) were analyzed. Median follow-up after initial GKRS was 15.6 years (range, 0.6-25.5 years). Median age at GKRS was 32.5 years (range, 16-53 years). Median number of meningiomas per patient was 13 (range, 1-27), and median number of convexity lesions receiving GKRS per patient was 3.5 (range, 1-27). One case of tumor progression was reported 24 years after GKRS, leading to actuarial progression-free survival rates of 100% at 2, 5, and 10 years. No malignant transformation or death due to meningioma or radiosurgery was recorded. CONCLUSIONS: GKRS is safe and effective as definitive treatment of small to medium-sized convexity meningiomas in patients with NF2. Despite concerns about the particular mutational burden of these tumors, no malignant transformation manifested after treatment. GKRS represents a minimally invasive option that offers long-term tumor control to this specific group of patients.
Authors: Stéphane Goutagny; Hong Wei Yang; Jessica Zucman-Rossi; Jennifer Chan; Jonathan M Dreyfuss; Peter J Park; Peter M Black; Marco Giovannini; Rona S Carroll; Michel Kalamarides Journal: Clin Cancer Res Date: 2010-08-03 Impact factor: 12.531
Authors: Brian J Williams; Chun Po Yen; Robert M Starke; Bhuvaneswara Basina; James Nguyen; Jessica Rainey; Jonathan H Sherman; David Schlesinger; Jason P Sheehan Journal: J Neurosurg Date: 2011-02-11 Impact factor: 5.115
Authors: Thien Nguyen; Lawrance K Chung; John P Sheppard; Nikhilesh S Bhatt; Cheng Hao Jacky Chen; Carlito Lagman; Tania Kaprealian; Percy Lee; Phioanh L Nghiemphu; Isaac Yang Journal: Neurosurg Rev Date: 2017-09-13 Impact factor: 3.042